Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

July 10, 2024 8:30 AM

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of Jules Haimovitz as a Strategic Advisor to the Company's executive management team."We are pleased to have Jules join Tharimmune in an advisory capacity," stated Randy Milby, CEO of Tharimmune. "We believe his extensive success in the...

Read more

Shining a Spotlight on IBS: Anatara Lifesciences Makes Strides in Phase II Trial during IBS Awareness Month

July 9, 2024 12:30 PM

April was IBS Awareness Month, dedicated to shedding light on a condition that affects millions worldwide.ADELAIDE, SOUTH AUSTRALIA / ACCESSWIRE / July 9, 2024 / In Australia alone, statistics reveal the profound impact of Irritable Bowel Syndrome (IBS) on individuals and the economy. With 1 in 7 Australians affected by IBS, predominantly females at a ratio of 2:1 to males , the condition exerts a significant toll. Notably, IBS costs the...

Read more

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

July 9, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe...

Read more

Dr. Alexander Sundermann Joins Next Gen Diagnostics as Its Director of Infection Prevention Services

July 9, 2024 8:00 AM

WEST PALM BEACH, FL / ACCESSWIRE / July 9, 2024 / Next Gen Diagnostics announces that Dr. Alexander Sundermann of the University of Pittsburgh School of Public Health, Department of Epidemiology has joined NGD as its Director of Infection Prevention Services. The part-time position will enable Dr. Sundermann to continue his research on the use of whole genome sequencing (WGS) to detect and curtail transmission of infection. Along with Dr. Lee...

Read more

Core One Enters into Loan Agreement with Right Season Investments

July 8, 2024 7:15 PM

Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has entered into a loan agreement (the "Loan Agreement") with Right Season Investments Corp. ("Right Season") dated June 28, 2024. Under the terms of the Loan Agreement, Right Season has advanced a loan of CDN$300,000 (the "Loan") to the Company. The Loan is repayable upon demand of Right Season and carries an...

Read more

Scailyte Strengthens Its Leadership

July 8, 2024 12:00 PM

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Darrin Crisitello as member of the BoDBASEL, SWITZERLAND / ACCESSWIRE / July 8, 2024 / Scailyte, a pioneer in single-cell and AI-driven biomarker discovery, is proud to announce the addition of three new members to its leadership team and BoD as the company continues to grow its business and to expand its presence in North America.Scailyte has...

Read more

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

July 8, 2024 6:30 AM

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapiesKVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumorsTo date, KVA12123 has demonstrated a favorable...

Read more

Repair Biotechnologies Announces Appointment of Noted Cardiologists to Scientific Advisory Board

July 3, 2024 9:00 AM

SYRACUSE, NY / ACCESSWIRE / July 3, 2024 / Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com/), a biotechnology company developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque, today announced the appointments of Ronald P. Karlsberg, MD, FACC, MSCCT, FAHA, FACP, and Daniel Karlsberg, MD, FACC, FSCCT to its Scientific Advisory Board (SAB). The SAB comprises experts in cardiology, biochemistry of...

Read more

GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences

July 2, 2024 9:00 AM

GB Sciences' Licensing Deal with Endopure Life Sciences will also include Rights to Develop and Market GB Sciences' Cannabinoid-based Treatments for a Suite of Neurological DisordersLAS VEGAS, NV / ACCESSWIRE / July 2, 2024 / GB Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, has signed a letter of intent outlining terms for a licensing deal with Endopure Life Sciences, LLC, a company...

Read more

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

July 1, 2024 8:35 AM

Kintara Therapeutics, Inc. (Nasdaq:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, and TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided an overview of Kintara's and TuHURA's recent corporate and clinical advancements and outlined upcoming expected near...

Read more

Biovica Signs New Agreement Supporting Pharma Development

June 28, 2024 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 28, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, a leader in blood-based cancer monitoring, has signed a Master Service Agreement and the initial Work Order with a US-based biopharmaceutical company specializing in breast cancer. The agreement enables Biovica to provide TKa testing services to support the development of new therapeutic treatments through pre-clinical and clinical...

Read more

Biovica International AB - Annual Report for the Financial Year 2023/2024 Published

June 28, 2024 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 28, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Annual report for the financial year 2023/2024 for Biovica International AB is published today on our website.See URL below.ContactAnders Rylander, CEOPhone: +46 76 666 16 47E-mail: [email protected] Morén, CFOPhone: +46 73 125 92 46E-mail: [email protected] - Treatment decisions with greater confidenceBiovica...

Read more

Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

June 27, 2024 12:45 PM

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.Proxy Voting ResultsOrdinary ResolutionsVotes for% of votes cast forVotes Against% of votes cast againstTotal votes castTotal votes cast as % of ISC (1)Votes with-held...

Read more

Form Bio and PacBio Announce Collaboration to Launch New Resources Set to Transform AAV Design and Analysis Best Practices

June 27, 2024 9:00 AM

Companies Form Expert Working Group to Introduce Essential Tools for AAV Development and Research ProfessionalsSAN FRANCISCO / ACCESSWIRE / June 27, 2024 / Form Bio, the provider of advanced computational life sciences technology and PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a range of new initiatives aimed at advancing and unifying the AAV industry. The initiatives,...

Read more

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

June 27, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides takeaways from Geoff Birkett, the Company's Chief Commercial Officer, following his participation on the opening panel of the European Pharmaceutical Market Research...

Read more

Clarification of Notice to Extraordinary General Meeting

June 27, 2024 4:50 AM

UPPSALA, SE / ACCESSWIRE / June 27, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The purpose of the extra general meeting that Biovica has called for on July 15, 2024, is to decide on share-based incentive programs for employees and the board of Biovica International AB and subsidiaries. By doing so at an extraordinary general meeting, the company avoids trading that the incentive program generates during the subscription...

Read more

Notice of the Extra General Meeting in Biovica International AB

June 27, 2024 3:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 27, 2024 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 15 July 2024, at 14:00 CET at Baker McKenzie's office at Vasagatan 7 in Stockholm.Right to attend the general meetingShareholders wishing to attend the general meeting must:i. on the...

Read more

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024

June 26, 2024 4:20 AM

Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be held in Rome, Italy, June 26 to 28, 2024 LUND, SE / ACCESSWIRE / June 26, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company...

Read more

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

June 26, 2024 2:20 AM

LUND, SE / ACCESSWIRE / June 26, 2024 / Alligator Bioscience (STO:ATORX)Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOXFurther deepening of tumor shrinkage was evident with additional objective responses over long treatment durationResults demonstrate an unprecedented median Duration of Response of 12.6 months and confirm...

Read more

Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025

June 25, 2024 2:45 PM

The board of directors of Alligator Bioscience AB (publ) (STO:ATORX) ("Alligator" or the "Company") has today resolved on a directed issue of convertibles to Fenja Capital II A/S ("Fenja") raising gross proceeds of SEK 12 million (the "Convertibles"). Furthermore, the Company has also entered into an agreement with Fenja for a loan facility of up to SEK 68 million (the "Loan Facility" and together with the Convertibles, the "Financing"). The...

Read more